# Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck

> **NCT02624999** · PHASE2 · WITHDRAWN · sponsor: **Mirror Biologics, Inc.**

## Conditions studied

- Squamous Cell Carcinoma Head and Neck

## Interventions

- **BIOLOGICAL:** AlloVax™
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02624999
- **Lead sponsor:** Mirror Biologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-12
- **Primary completion:** 2016-12
- **Final completion:** 2017-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI changed institution
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02624999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02624999, "Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02624999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*